Next Article in Journal
Novel Flu Viruses in Bats and Cattle: “Pushing the Envelope” of Influenza Infection
Next Article in Special Issue
CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma
Previous Article in Journal
Development of a Sensitive Real-Time Fast-qPCR Based on SYBR® Green for Detection and Quantification of Chicken Parvovirus (ChPV)
 
 
Article

Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma

Unidad de Transferencia Genética, Instituto de Oncología “Ángel H. Roffo”, Universidad de Buenos Aires, Av. San Martín 5481, 1417 Buenos Aires, Argentina
*
Author to whom correspondence should be addressed.
Vet. Sci. 2018, 5(3), 70; https://doi.org/10.3390/vetsci5030070
Received: 21 June 2018 / Revised: 20 July 2018 / Accepted: 31 July 2018 / Published: 3 August 2018
(This article belongs to the Special Issue Canine Cancer Immunotherapeutics)
The incidence of canine mammary carcinoma varies with age, breed, and spay status, being among the main tumors appearing in intact female dogs. Thirty-six canine mammary carcinoma patients received injections of canine interferon-β (cIFN-β) and HSV-thymidine kinase/ganciclovir (HSV-tk/GCV) carrying lipoplexes, into the tumor bed, immediately after surgery. Next, they started periodic subcutaneous injections of lipoplexes carrying a human granulocyte-macrophage colony stimulating factor and interleukin-2 mixed with allogeneic mammary carcinoma extracts. This combined strategy was safe and well tolerated. In addition, only two out of 26 patients treated with complete surgery developed a local relapse, and 0 out of 29 stage II and III patients displayed distant metastases, suggesting both local and systemic antitumor activities. The most encouraging result was the long survival times: 22 > 1 year (where 13 > 2 and 4 > 3 years), while maintaining a good quality of life. The preliminary results in five patients presenting with local disease, an additional HSV-tk/GCV plus cIFN-β gene treatment induced local antitumor activity, evidenced by four objective responses (one complete, three partial) and one stable disease. This successful outcome supports further studies to validate this approach not only for canine veterinary patients, but also for translation to human patients. View Full-Text
Keywords: IL-2; GM-CSF; HSV-tk; IFN-β; canine mammary carcinoma; cancer vaccine; lipofection; DMRIE; gene therapy IL-2; GM-CSF; HSV-tk; IFN-β; canine mammary carcinoma; cancer vaccine; lipofection; DMRIE; gene therapy
Show Figures

Figure 1

MDPI and ACS Style

Finocchiaro, L.M.E.; Spector, A.I.M.; Agnetti, L.; Arbe, M.F.; Glikin, G.C. Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma. Vet. Sci. 2018, 5, 70. https://doi.org/10.3390/vetsci5030070

AMA Style

Finocchiaro LME, Spector AIM, Agnetti L, Arbe MF, Glikin GC. Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma. Veterinary Sciences. 2018; 5(3):70. https://doi.org/10.3390/vetsci5030070

Chicago/Turabian Style

Finocchiaro, Liliana M. E., Agustina I. M. Spector, Lucrecia Agnetti, M. Florencia Arbe, and Gerardo C. Glikin. 2018. "Combination of Suicide and Cytokine Gene Therapies as Surgery Adjuvant for Canine Mammary Carcinoma" Veterinary Sciences 5, no. 3: 70. https://doi.org/10.3390/vetsci5030070

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop